NASDAQ$AMLX
Amylyx Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported strong financial results driven by commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada.
Amylyx Pharmaceuticals reported strong financial results for the second quarter of 2023, with product revenue of $98.2 million and net income of $22.1 million. The company's commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada continued to progress.
- Second quarter product revenue reached $98.2 million, driven by demand and insurance coverage for RELYVRIO in the U.S. and ALBRIOZA in Canada.
- Net income for the second quarter was $22.1 million.
- Cash, cash equivalents, and short-term investments totaled $357.3 million as of June 30, 2023.
- Plans are underway to initiate a global, pivotal Phase 3 trial of AMX0035 for the treatment of progressive supranuclear palsy (PSP).
Headline financials
Revenue & EPS history
Amylyx · Revenue · Quarterly
$98.2M
Forward guidance
Amylyx is focused on the commercialization of RELYVRIO and ALBRIOZA, as well as the development of AMX0035 for other neurodegenerative diseases.
Tailwinds
- Continued progress in commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada.
- Expected ALBRIOZA coverage to be in place for the vast majority of publicly insured lives in Canada by the end of August.
- Plans to initiate a global Phase 3 ORION trial of AMX0035 for the treatment of progressive supranuclear palsy later this year.
- Phase 2 HELIOS study of AMX0035 for the treatment of Wolfram syndrome is enrolling participants, with topline results expected next year.
- Marketing Authorisation Application (MAA) for AMX0035 for the treatment of ALS under review with the European Medicines Agency’s (EMA).
Headwinds
- Received a negative opinion from the CHMP in June regarding the MAA and requested a formal re-examination.
- Re-examination procedure is an approximately four-month process, with a final opinion expected in fall 2023.
- Risk in Patients with Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders
- RELYVRIO has a high salt content.
- The most common adverse reactions (at least 15% and at least 5% greater than placebo) with RELYVRIO were diarrhea, abdominal pain, nausea, and upper respiratory tract infection.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2023
+0.3%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+7.4%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.4%
Q4 2021
Best reaction
-30.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -7.6% | -9.5% | -2.3% | |
| Q3 2025 | -5.9% | -4.2% | +7.3% | |
| Q1 2025 | -6.0% | -7.8% | +9.4% | |
| Q4 2024 | +0.3% | +29.0% | +17.0% | |
| Q3 2024 | +7.7% | +0.3% | -17.4% | |
| Q2 2024 | +1.1% | +5.9% | +26.1% | |
| Q1 2024 | -8.8% | -3.1% | -8.3% | |
| Q4 2023 | +15.3% | +24.1% | -82.1% | |
| Q3 2023 | -30.7% | -30.4% | -22.2% | |
| Q2 2023 | +0.5% | -2.3% | -4.5% | |
| Q1 2023 | -4.4% | -6.1% | -11.9% | |
| Q4 2022 | +11.2% | -1.2% | -3.9% | |
| Q3 2022 | -1.8% | +2.4% | +3.0% | |
| Q3 2021 | -1.8% | +2.4% | +3.0% | |
| Q2 2021 | -5.5% | -5.7% | +12.7% | |
| Q2 2022 | -5.5% | -5.7% | +12.7% | |
| Q4 2021 | +23.4% | +28.2% | +97.5% | |
| Q1 2022 | +23.4% | +28.2% | +97.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro